Sanofi's Blood Cancer Drug's New Subcutaneous Formulation Hits Primary Goal In Late-Stage ...
Sanofi's phase 3 study shows Sarclisa SC matches IV formulation in efficacy for relapsed myeloma. Regulatory submissions are planned for 2025.
Bradford Era6 天
Penn State has golden opportunity to become one of college football's elite programs
The Penn State Nittany Lions have reached the national semifinals for the first time in program history (in the playoff era) after beating two inferior opponents in the previous rounds.